Short radiation course for metastatic rectal cancer symptoms
Part of Cancer, Digestive system clinical trials.
This trial tests whether a brief course of radiation therapy can help relieve symptoms like bleeding, pain, or blockage for people with metastatic rectal cancer that can't be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal cancer that has spread to other parts of the body and cannot be removed by surgery.
- You have symptoms such as bleeding, pain, feeling like you need to pass stool, or a blocked bowel.
- You have not had radiation therapy before for this cancer.
- You are not currently receiving chemotherapy.
- You do not already have a colostomy or ileostomy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a short course of radiation therapy combined with chemotherapy and immunotherapy for people with mid-to-low rectal cancer that hasn't spread. It aims to see if this combination can shrink the tumor and improve outcomes.
This trial tests a short course of radiation given before chemotherapy for people with locally advanced rectal cancer (cancer that has grown into nearby tissue and/or nearby lymph nodes but can still be removed). It may help shrink the tumor and make treatment more effective while assessing how well this approach works.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy before surgery for high-risk rectal cancer. The goal is to see if this combination shrinks the tumor more effectively and improves outcomes.
This trial tests a short course of radiation therapy combined with chemotherapy for people with stage II or III rectal cancer. It’s designed to see whether this approach is safe and effective before or around cancer surgery.
This trial tests a combination of brief radiation therapy, two chemotherapy drugs (nal-IRI and capecitabine), and an immunotherapy drug (camrelizumab) for locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes before surgery.
This study looks at molecular (tumor biology) features of rectal cancer in people receiving standard short-course radiation. Your tissue and/or samples may be used to better understand the cancer and how it responds to treatment.
Hear when a new Metastatic Cancer Rectum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.